Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05557110
Other study ID # SZ-ALL02
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 8, 2022
Est. completion date March 31, 2024

Study information

Verified date April 2024
Source The First Affiliated Hospital of Soochow University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Blinatumomab, a CD3/CD19 bisespecific T-cell conjugative antibody, has shown high efficacy in phase I/II studies of relapsed/refractory B-lymphoblastic leukemia (B-ALL), particularly in the context of low tumor burden.Meanwhile, Blinatumomab also plays an important role in rapid and efficient clearance of MRD in patients. Therefore, its use in combination with less intensive chemotherapy for initial induction therapy in newly diagnosed patients may result in favorable response rates, greater depth of remission, and lower treatment-related toxic effects. In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and treated with reduced-intensity chemotherapy followed by Blinatumomab as the basis of induction therapy. The clinical remission rate, MRD negative rate and treaty-related adverse reactions were evaluated in newly diagnosed non-elderly PH-B-ALL patients during induction therapy.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date March 31, 2024
Est. primary completion date January 5, 2024
Accepts healthy volunteers No
Gender All
Age group 15 Years to 65 Years
Eligibility Inclusion Criteria: 1. Age 15-59 2. Ph-(BCR-ABL1 negative)B-ALL was diagnosed according to WHO diagnostic criteria 3. Newly diagnosed patients without prior induction therapy (except hydroxyurea and glucocorticoids ?5 days) 4. ECOG score 0-3 5. Liver function: total bilirubin ? 3 times the upper limit of normal; Alanine aminotransferase ? 3 times upper limit of normal motion; Aspartate aminotransferase ? 3 times upper limit of normal motion; (except considering leukemia infiltration) 6. Renal function: endogenous creatinine clearance ?30ml/min 7. Patients must be able to understand and willing to participate in the study and must sign the informed consent form. Exclusion Criteria: 1. Ph+ (BCR-ABL1 positive) ALL and known ABL class Ph-Like ALL 2. T cells ALL 3. Mature B-cell leukemia/lymphoma, B-cell lymphoma, isolated extramedullary disease 4. Acute mixed-cell leukemia 5. Central nervous system leukemia 6. HIV infection 7. HBV-DNA or HCV-RNA positive 8. Patients with grade 2 or higher heart failure and other patients deemed inappropriate for inclusion by the investigator 9. Pregnant or breastfeeding patients 10. The study patient was refused enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Blinatumomab
Reduced-intensity chemotherapy followed by Blinatumomab

Locations

Country Name City State
China The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology Suzhou Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Chen Suning

Country where clinical trial is conducted

China, 

References & Publications (3)

Fleming, S. et al. Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study. Blood 138, 1234-1234, doi:10.1182/blood-2021-151826 (2021).

Gokbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Bruggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22. Erratum In: Blood. 2019 Jun 13;133(24):2625. — View Citation

Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, Viardot A, Marks R, Diedrich H, Faul C, Reichle A, Horst HA, Bruggemann M, Wessiepe D, Holland C, Alekar S, Mergen N, Einsele H, Hoelzer D, Bargou RC. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014 Dec 20;32(36):4134-40. doi: 10.1200/JCO.2014.56.3247. Epub 2014 Nov 10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Overall response rate (ORR) Overall response rate (ORR), including complete response (CR)/ complete response rate with partial hematologic recovery (CRh)/ complete response rate with incomplete hematologic recovery (CRi). Induction therapy phase: The time of bone marrow evaluation is day 22 or 37±2.
Secondary The negative rate of minimal residual lesion (MRD) The negative rate of minimal residual lesion (MRD) during induction therapy (The threshold is 1×10^-4) Induction therapy phase: The time of bone marrow evaluation is day 22 or 37±2.
Secondary Treatment-related SAE Incidence of treatment-related severe adverse events, including severe bleeding, infection, drug-related adverse events, and organ dysfunction. From the beginning of induction therapy to the beginning of consolidation therapy.
Secondary Time of hematopoietic recovery The duration of the patient in the granulocytic deficiency and thrombocytopenia phases. From the beginning of induction therapy to the beginning of consolidation therapy.
Secondary Event-free survival (EFS) The time from enrollment to the occurrence of any event, including death, progression of disease, change in treatment regimen, and occurrence of fatal or intolerable side effects. 1 year after study completion
Secondary Overall survival (OS) From the time of enrollment in the study to the time of death from any cause. 1 year after study completion
See also
  Status Clinical Trial Phase
Recruiting NCT04872790 - Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia Phase 1
Active, not recruiting NCT02458014 - Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease Phase 2
Active, not recruiting NCT03233854 - CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies Phase 1
Recruiting NCT03959085 - Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Phase 3
Recruiting NCT03856216 - Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation Phase 2
Recruiting NCT03241940 - Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies Phase 1
Active, not recruiting NCT02484430 - Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia Phase 2
Active, not recruiting NCT02146924 - Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia Phase 1
Recruiting NCT02877303 - Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia Phase 2
Terminated NCT03488225 - Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT02968472 - A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia Phase 1
Recruiting NCT05157971 - Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia Phase 1
Recruiting NCT05310591 - Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence Phase 1/Phase 2
Active, not recruiting NCT02143414 - Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia Phase 2
Completed NCT03289455 - CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) Phase 1/Phase 2
Suspended NCT03150693 - Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia Phase 3
Not yet recruiting NCT06317662 - Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Phase 2
Recruiting NCT03914625 - A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Phase 3
Not yet recruiting NCT06124157 - A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) Phase 3
Withdrawn NCT02538926 - Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Phase 2